Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Conditions: Hepatocellular Carcinoma Interventions: Drug: Alectinib (Alecensa), Nivolumab (Opdivo) Sponsors: China Medical University Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials